Compare Gilead Sciences, Inc. (GILD) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Invesco S&P 500 Momentum ETF — how do they compare? Gilead Sciences, Inc. trades at $151.23 (market cap $182.40B), while Invesco S&P 500 Momentum ETF trades at $151.33 (market cap $23.48B). The key difference: Gilead Sciences, Inc. is far larger — about 7.8× Invesco S&P 500 Momentum ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Invesco S&P 500 Momentum ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Invesco S&P 500 Momentum ETF for 54 Days on average.
| GILD | SPMO | |
|---|---|---|
Market Cap | $182.40B | $23.48B |
Volume | 4,469,821 | 1,876,152 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $161.66 |
52-Week Low | $116.74 | $107.84 |
Typical Hold Time | 111 Days | 54 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
SPMO trades at $153.00, showing minimal daily movement with a 0.01% gain. The ETF maintains a bullish technical outlook with strong moving average signals, though oscillators suggest neutral momentum. Recent portfolio reconstitution added 54 stocks including Apple and Merck, while removing Nvidia. Institutional interest remains strong with Envestnet Asset Management increasing its stake by 9.5% in Q2 2026.
The momentum-focused ETF offers concentrated exposure to S&P 500's fastest-rising stocks, historically outperforming the broader index. Key risks include sector concentration in technology and higher volatility. Analyst sentiment remains positive given the fund's structural momentum advantage and institutional accumulation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
